Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments (DETECSEPS)
Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection
DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.
The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.
The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.
In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.
In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.
The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.
IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Djillali Annane
- Phone Number: +33 +33 1 47 10 77 87
- Email: djillali.annane@aphp.fr
Study Contact Backup
- Name: Sébastien Beaune, MD PhD
- Phone Number: +33 +33 1 49 09 46 56
- Email: sebastien.beaune@aphp.fr
Study Locations
-
-
-
Boulogne-Billancourt, France
- Hôpital Ambroise Paré - AP-HP
-
Contact:
- Sébastien Beaune, MD PhD
- Phone Number: +33 +33 1 49 09 46 56
- Email: sebastien.beaune@aphp.fr
-
Lyon, France
- Hôpital de la Croix Rousse - HCL
-
Contact:
- Youri Yordanov
- Phone Number: +33 +33 4 72 11 00 28
- Email: youri.yordanov@chu-lyon.fr
-
Lyon, France
- Hôpital Lyon Sud - HCL
-
Contact:
- Marion Douplat
- Phone Number: +33 +33 4 78 86 20 63
- Email: marion.douplat@chu-lyon.fr
-
Lyon, France
- Hôpital Édouard-Herriot - HCL
-
Contact:
- Karim Tarazourte
- Phone Number: +33 +33 4 72 11 00 40
- Email: karim.tazarourte@chu-lyon.fr
-
Paris, France
- Hôpital Bichat - AP-HP
-
Contact:
- Donia Bouzid
- Phone Number: +33 01 40 25 77 66
- Email: donia.bouzid@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
-
All genders patients
-
Aged of 18 years or older
-
Proven or suspected infection
-
At least one risk factor for sepsis (cf HAS recommendations) :
-
Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery
-
Inborn immune deficit
-
Acquired immune deficit :
- Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease)
- Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,
-
Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis
-
-
Informed consent
Exclusion Criteria:
- Refused to consent participating in the study,
- Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
- Previous enrolment
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NEWS2 and H3.1-guided diagnostic and management strategy
Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol. Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below :
|
This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system. The result will not be disclosed to the investigators and healthcare staff in the control arm The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:
The result will not be disclosed to the investigators and healthcare staff in the control arm |
|
Other: Usual care
Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians. |
This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system. The result will not be disclosed to the investigators and healthcare staff in the control arm The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:
The result will not be disclosed to the investigators and healthcare staff in the control arm |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with optimized care pathway
Time Frame: 24 hours after inclusion
|
The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission If sepsis is confirmed:
|
24 hours after inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Death rate
Time Frame: At 6 months
|
At 6 months
|
|
|
Cumulative incidence of direct ICU admission
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Cumulative incidence of secondary ICU admission
Time Frame: Up to 6 months
|
ie after admission to ward |
Up to 6 months
|
|
Proportion of patients with cognitive, psychological, or physical sequelae
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Proportion of patients requiring renal, respiratory, or cardiovascular support
Time Frame: Up to day 7
|
Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery |
Up to day 7
|
|
Proportion of patients requiring renal, respiratory, or cardiovascular support
Time Frame: Up to day 28
|
Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery |
Up to day 28
|
|
Time to discharge to home
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Time to resume previous social and professional activities
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Quality of life - EQ-5D-5L
Time Frame: At 6 months
|
The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status |
At 6 months
|
|
Quality of life - SF36
Time Frame: At 6 months
|
The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning. |
At 6 months
|
|
Cost of strategies and care pathways
Time Frame: At 6 months
|
Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months. |
At 6 months
|
|
Proportion of cases for which the combined diagnostic protocol is applied as intended
Time Frame: Up to 6 months
|
e.g., correct use of NEWS2 and H3.1 nucleosome testing |
Up to 6 months
|
|
Proportion of test results available below a meaningful clinical duration to allow for patient management.
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Proportion of appropriate integration of tests results within clinical workflow
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Proportion of avoided hospitalization among patients receiving the intervention
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Evolution of the proportion of eligible patients included over time
Time Frame: Up to 6 months
|
Up to 6 months
|
|
|
Environmental impact of study-related procedures
Time Frame: Up to 6 months
|
The environmental footprint of each component of the research process will be assess, including:
All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study. |
Up to 6 months
|
|
Life cycle analyse (LCA)
Time Frame: Up to 6 months
|
Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools. |
Up to 6 months
|
|
LCA comparison of the two clinical strategies
Time Frame: Up to 6 months
|
The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes. The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study. |
Up to 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines
Time Frame: At baseline, day 1 and day 7
|
At baseline, day 1 and day 7
|
|
|
Multi-omic profile
Time Frame: At baseline
|
Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed. |
At baseline
|
|
Multi-omic profile
Time Frame: At day 1
|
Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed. |
At day 1
|
|
Multi-omic profile
Time Frame: At day 7
|
Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed. |
At day 7
|
|
Innate immune cells activation markers and sub-populations
Time Frame: At baseline
|
Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. |
At baseline
|
|
Innate immune cells activation markers and sub-populations
Time Frame: At day 1
|
Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. |
At day 1
|
|
Innate immune cells activation markers and sub-populations
Time Frame: At day 7
|
Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. |
At day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Djillali Annane, MD PhD, IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- APHP260617
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP
IPD Sharing Time Frame
Within 6 months from publication of the study results
IPD Sharing Access Criteria
Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.